Related Experiment Video
Updated: Jul 12, 2026
09:46
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
Published on: September 21, 2021
Cognitive dysfunction in multiple sclerosis: a review of recent developments
Julie A Bobholz1, Stephen M Rao
1Department of Neurology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA. jbobholz@mcw.edu
Current Opinion in Neurology
|July 15, 2003
Summary
Cognitive dysfunction impacts nearly half of multiple sclerosis patients, affecting daily living. Disease-modifying therapies may slow cognitive decline and improve daily activities by reducing MRI-visible disease activity.
Area of Science:
- Neuroscience
- Neurology
- Clinical Medicine
Background:
- Cognitive dysfunction affects nearly half of multiple sclerosis (MS) patients.
- This cognitive impairment is linked to a significant decline in daily living activities.
- Understanding and managing cognitive issues in MS is crucial for patient quality of life.
Purpose of the Study:
- To review recent literature on cognitive dysfunction in multiple sclerosis (MS).
- To explore the relationship between cognitive deficits and daily functioning in MS.
- To examine potential treatments and neurobiological correlates of cognitive impairment in MS.
Main Methods:
- Literature review of recent studies on MS cognitive dysfunction.
- Analysis of studies examining cognitive processes, natural history, and daily living skills.
- Inclusion of research focusing on neuroimaging correlates and treatment investigations.
Main Results:
- Increased understanding of specific cognitive processes affected in MS and its natural history.
- Strong association between cognitive deficits and decline in daily living skills, including driving.
- Neuroimaging techniques reveal correlations between disease activity/lesion burden and cognitive deficits.
- Emerging research on potential treatments for cognitive dysfunction in MS.
Conclusions:
- Disease-modifying medications show potential in impacting MRI-visible disease activity.
- These therapies may slow the progression of cognitive decline over time.
- Treatment may lead to improved activities of daily living for patients with multiple sclerosis.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Negative and Cognitive Symptoms of Schizophrenia
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...